These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 8629886

  • 21. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy.
    Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, Rapoport SI, Rapoport JL, Grady CL.
    Arch Gen Psychiatry; 1992 Sep; 49(9):690-4. PubMed ID: 1514873
    [Abstract] [Full Text] [Related]

  • 22. Normal caudate nucleus in obsessive-compulsive disorder assessed by quantitative neuroimaging.
    Aylward EH, Harris GJ, Hoehn-Saric R, Barta PE, Machlin SR, Pearlson GD.
    Arch Gen Psychiatry; 1996 Jul; 53(7):577-84. PubMed ID: 8660124
    [Abstract] [Full Text] [Related]

  • 23. Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder.
    Saxena S, Gorbis E, O'Neill J, Baker SK, Mandelkern MA, Maidment KM, Chang S, Salamon N, Brody AL, Schwartz JM, London ED.
    Mol Psychiatry; 2009 Feb; 14(2):197-205. PubMed ID: 18180761
    [Abstract] [Full Text] [Related]

  • 24. Impact of treatment on resting cerebral blood flow and metabolism in obsessive compulsive disorder: a meta-analysis.
    van der Straten AL, Denys D, van Wingen GA.
    Sci Rep; 2017 Dec 12; 7(1):17464. PubMed ID: 29234089
    [Abstract] [Full Text] [Related]

  • 25. Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder.
    Kwon JS, Kim JJ, Lee DW, Lee JS, Lee DS, Kim MS, Lyoo IK, Cho MJ, Lee MC.
    Psychiatry Res; 2003 Jan 20; 122(1):37-47. PubMed ID: 12589881
    [Abstract] [Full Text] [Related]

  • 26. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder.
    Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter LR.
    Neuropsychopharmacology; 1999 Dec 20; 21(6):683-93. PubMed ID: 10633474
    [Abstract] [Full Text] [Related]

  • 27. Differences in metabolic network modulation between capsulotomy and deep-brain stimulation for refractory obsessive-compulsive disorder.
    Suetens K, Nuttin B, Gabriëls L, Van Laere K.
    J Nucl Med; 2014 Jun 20; 55(6):951-9. PubMed ID: 24722531
    [Abstract] [Full Text] [Related]

  • 28. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder.
    Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland R, Rapoport SI, Rapoport JL.
    Arch Gen Psychiatry; 1989 Jun 20; 46(6):518-23. PubMed ID: 2786402
    [Abstract] [Full Text] [Related]

  • 29. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography.
    Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HC, Savage CR, Fischman AJ.
    Arch Gen Psychiatry; 1994 Jan 20; 51(1):62-70. PubMed ID: 8279930
    [Abstract] [Full Text] [Related]

  • 30. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
    Kim E, Howes OD, Park JW, Kim SN, Shin SA, Kim BH, Turkheimer FE, Lee YS, Kwon JS.
    Psychol Med; 2016 Jan 20; 46(2):357-66. PubMed ID: 26423910
    [Abstract] [Full Text] [Related]

  • 31. Volumetric analysis and three-dimensional glucose metabolic mapping of the striatum and thalamus in patients with autism spectrum disorders.
    Haznedar MM, Buchsbaum MS, Hazlett EA, LiCalzi EM, Cartwright C, Hollander E.
    Am J Psychiatry; 2006 Jul 20; 163(7):1252-63. PubMed ID: 16816232
    [Abstract] [Full Text] [Related]

  • 32. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder.
    Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, Baxter LR.
    Psychiatry Res; 1998 Nov 09; 84(1):1-6. PubMed ID: 9870412
    [Abstract] [Full Text] [Related]

  • 33. Neuroimaging communality between schizophrenia and obsessive compulsive disorder: a putative basis for schizo-obsessive disorder?
    Gross-Isseroff R, Hermesh H, Zohar J, Weizman A.
    World J Biol Psychiatry; 2003 Jul 09; 4(3):129-34. PubMed ID: 12872207
    [Abstract] [Full Text] [Related]

  • 34. Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography.
    Martin WR, Hoskinson M, Kremer B, Maguire C, McEwan A.
    J Neuroimaging; 1995 Oct 09; 5(4):227-32. PubMed ID: 7579751
    [Abstract] [Full Text] [Related]

  • 35. Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive-compulsive disorder.
    Kang DH, Kwon JS, Kim JJ, Youn T, Park HJ, Kim MS, Lee DS, Lee MC.
    Acta Psychiatr Scand; 2003 Apr 09; 107(4):291-7. PubMed ID: 12662252
    [Abstract] [Full Text] [Related]

  • 36. Regional cerebral glucose metabolism in bulimia nervosa.
    Andreason PJ, Altemus M, Zametkin AJ, King AC, Lucinio J, Cohen RM.
    Am J Psychiatry; 1992 Nov 09; 149(11):1506-13. PubMed ID: 1415817
    [Abstract] [Full Text] [Related]

  • 37. Orbito-frontal cortex and thalamus volumes in the patients with obsessive-compulsive disorder before and after cognitive behavioral therapy.
    Atmaca M, Yildirim H, Yilmaz S, Caglar N, Mermi O, Korkmaz S, Akaslan U, Gurok MG, Kekilli Y, Turkcapar H.
    Int J Psychiatry Med; 2018 Jul 09; 53(4):243-255. PubMed ID: 26740455
    [Abstract] [Full Text] [Related]

  • 38. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18.
    Baxter LR, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, Sumida RM.
    Arch Gen Psychiatry; 1985 May 09; 42(5):441-7. PubMed ID: 3872649
    [Abstract] [Full Text] [Related]

  • 39. Regional xenon 133 cerebral blood flow and cerebral technetium 99m HMPAO uptake in unmedicated patients with obsessive-compulsive disorder and matched normal control subjects. Determination by high-resolution single-photon emission computed tomography.
    Rubin RT, Villanueva-Meyer J, Ananth J, Trajmar PG, Mena I.
    Arch Gen Psychiatry; 1992 Sep 09; 49(9):695-702. PubMed ID: 1514874
    [Abstract] [Full Text] [Related]

  • 40. Decreased caudate N-acetyl-l-aspartic acid in pediatric obsessive-compulsive disorder and the effects of behavior therapy.
    Whiteside SP, Abramowitz JS, Port JD.
    Psychiatry Res; 2012 Apr 30; 202(1):53-9. PubMed ID: 22704757
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.